Glyco-metabolic control, inflammation markers, and cardiovascular outcomes in type 1 and type 2 diabetic patients on insulin pump or multiple daily injection (italico study).
Giuseppe DerosaGabriele CatenaLaura ScelsiAngela D'AngeloRiccardo RaddinoEugenio CosentinoAntonio MaggiGianfranco PasiniClaudio BorghiPamela MaffioliPublished in: Diabetes/metabolism research and reviews (2019)
Our preliminary data suggest that CSII treatment seems to reduce the rates of CV compared with MDI therapy. Moreover, CSII also improved glycaemic control, without increasing the number of hypoglycaemia. However, given the observational design of this trial, our data should be validated in a randomized clinical trial; if they will be confirmed, CSII could be chosen for fully informed and motivated patients at higher risk of developing CV.
Keyphrases
- type diabetes
- electronic health record
- big data
- oxidative stress
- clinical trial
- study protocol
- physical activity
- phase iii
- glycemic control
- phase ii
- cross sectional
- combination therapy
- metabolic syndrome
- adipose tissue
- insulin resistance
- mesenchymal stem cells
- data analysis
- bone marrow
- open label
- deep learning
- artificial intelligence
- double blind